| P50 | author | Kenneth Blum | Q6389872 |
| | Edward J Modestino | Q57225621 |
| | Marjorie C Gondré-Lewis | Q95975797 |
| | Bruce Steinberg | Q114407809 |
| | Mary Hauser | Q114407813 |
| | David B Siwicki | Q114407814 |
| | Jennifer Neary | Q114407815 |
| | Rajendra Badgaiyan | Q19938391 |
| | Debmalya Barh | Q30001971 |
| P2860 | cites work | Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin | Q41245913 |
| | Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence | Q42375786 |
| | Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States | Q44333134 |
| | Trends in opioid analgesic abuse and mortality in the United States | Q44350712 |
| | Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial | Q44626401 |
| | Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations | Q44927023 |
| | Neurocognitive variation in smoking behavior and withdrawal: genetic and affective moderators | Q45285800 |
| | Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatricgenetic research of complex behavioral disorders | Q46287440 |
| | Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. | Q52275787 |
| | The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. | Q55331780 |
| | THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS | Q56892520 |
| | Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment | Q60682780 |
| | Association between the D2 dopamine receptor gene and alcoholism. A continuing controversy | Q67961284 |
| | What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics? | Q71552324 |
| | The genetic basis of addictive disorders | Q24607129 |
| | Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS) | Q28652508 |
| | Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials | Q31138857 |
| | Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome | Q31140973 |
| | The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction | Q33579769 |
| | Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. | Q33609822 |
| | Genetic risk prediction and neurobiological understanding of alcoholism | Q33672725 |
| | Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. | Q34304684 |
| | CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. | Q34518212 |
| | Allelic association of human dopamine D2 receptor gene in alcoholism | Q34998499 |
| | Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population | Q35016329 |
| | Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? | Q35053937 |
| | Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence | Q35085081 |
| | Transcriptome organization for chronic alcohol abuse in human brain. | Q35674997 |
| | Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward | Q36234280 |
| | Pharmacogenetics of opioid receptors and addiction | Q36339767 |
| | Nonmedical Prescription Opioid Use in Childhood and Early Adolescence Predicts Transitions to Heroin Use in Young Adulthood: A National Study | Q36468218 |
| | Dopamine Genetics and Function in Food and Substance Abuse | Q36718951 |
| | Using genetic information from candidate gene and genome-wide association studies in risk prediction for alcohol dependence | Q36876237 |
| | Gene x abstinence effects on drug cue reactivity in addiction: multimodal evidence | Q36928468 |
| | rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts | Q37164595 |
| | Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood | Q37280300 |
| | Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring | Q37876422 |
| | The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response | Q38533533 |
| | Alterations in brain connectivity in three sub-regions of the anterior cingulate cortex in heroin-dependent individuals: Evidence from resting state fMRI. | Q39090343 |
| | Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014. | Q39454258 |
| | The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem | Q40468073 |
| | The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. | Q40575056 |
| | Candidate genes in alcoholism. | Q40976810 |
| P433 | issue | 1 | |
| P304 | page(s) | 17-22 | |
| P577 | publication date | 2017-11-18 | |
| P1476 | title | GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA | |
| P478 | volume | 2 | |